This triple-agonist approach, targeting GLP-1, GIP, and glucagon receptors, produced the most dramatic weight loss results seen in any Phase 2 obesity trial
These findings emphasize the need for further research to understand the differential effects of these medications
Common Digestive Changes Patients Notice As gut motility slows, some patients experience: Constipation Bloating or pressure after meals Early fullness Mild nausea Reduced hunger cues These effects are most common during dose increases or early treatment and usually improve with proper support
Experts recommend recovering by drinking plenty of fluids, avoiding solid foods, and resting if you are experiencing norovirus symptoms
Patients often report a more even skin tone, reduced dullness, and improved skin radiance when combined with Vitamin C and hydration therapy